Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Grant Support/Research Contract (Institutional) - Abbott Vascular; AstraZenca; Bayer AG; Boston Scientific Corporation; Bristol-Myers Squibb; Medtronic; Sanofi-Aventis; The Medicines Company; Amgen; Idorsia; PhaseBio; Pfizer; Regeneron; Ironwood; Ischemix; Synaptic; Amarin; 89Bio; Boehringer Ingelheim; Afimmune; Chiesi; CSL Behring; PLx Pharma; Lexicon